Satellite Symposium at the 8th Congress of the European Society of Gynecology
Selective progesterone receptor modulators (SPRM) are a new class of compounds with great potential in the treatment of uterine fibroids. The presentations in this symposium discussed the pharmacology of SPRM and their effect on the endometrium, before moving on to review recent clinical outcomes with SPRM and identifying how they might be used in the management of uterine fibroids.
Hall Pio X, MONUMENTAL COMPLEX OF SANTO SPIRITO IN SAXIA, Borgo Santo Spirito 1, 00193 Rome, Italy
Friday, 11th September 2009 | 09:10 – 10:40
The IP address 192.168.1.254 Admin Login is a private IP address which implies it will fit up to a specific range which is held from IANA as a private range. For the most part when we buy another switch or modem they give username and secret word. This username and secret key will shield you from pointless associations.
Bart Fauser, The Netherlands
Andrea Genazzani, Italy
- 09:10 – 09:15 | Introduction: Why clinicians must re-evaluate what they can offer symptomatic patients | Bart Fauser, The Netherlands
- 09:15 – 09:35 | SPRM class: Mode of action, and do SPRMs differ from each other? | Philippe Bouchard, France
- 09:35 – 09:55 | Features of selective progesterone receptor modulator (SPRM) associated endometrial changes | George Mutter, USA
- 09:55 – 10:15 | The proof of evidence: PGL4001 (ulipristal acetate) Phase II clinical data| Lynnette Nieman, USA
- 10:15 – 10:35 | SPRMs in clinical practice: Are there any implications for surgery? | Jacques Donnez, Belgium
- 10:35 – 10:40 | Question and answer session | Andrea Genazzani, Italy